We are contrasting Anika Therapeutics Inc. (NASDAQ:ANIK) and Zealand Pharma A/S (NASDAQ:ZEAL) on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Anika Therapeutics Inc. and Zealand Pharma A/S. Zealand Pharma A/S appears to has lower revenue, but higher earnings than Anika Therapeutics Inc. Business that presently has a higher P/E ratio means that it is the more expensive of the two businesses. Anika Therapeutics Inc. is presently more expensive than Zealand Pharma A/S, because it’s trading at a higher P/E ratio.

Profitability

Table 2 provides the return on assets, return on equity and net margins of the two firms.

Analyst Ratings

Recommendations and Ratings for Anika Therapeutics Inc. and Zealand Pharma A/S can be find in next table.

Competitively Zealand Pharma A/S has an average target price of $30, with potential upside of 26.80%.

Institutional and Insider Ownership

Institutional investors held 96.6% of Anika Therapeutics Inc. shares and 9% of Zealand Pharma A/S shares. About 0.9% of Anika Therapeutics Inc.’s share are held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Anika Therapeutics Inc.’s stock price has smaller growth than Zealand Pharma A/S.

Summary

On 8 of the 14 factors Anika Therapeutics Inc. beats Zealand Pharma A/S.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.